ANL 32.21 Increased By ▲ 0.51 (1.61%)
ASC 18.65 Increased By ▲ 1.20 (6.88%)
ASL 26.45 Decreased By ▼ -0.15 (-0.56%)
AVN 91.35 Increased By ▲ 0.85 (0.94%)
BOP 8.21 Increased By ▲ 0.03 (0.37%)
BYCO 11.84 Increased By ▲ 0.49 (4.32%)
DGKC 126.00 Decreased By ▼ -2.50 (-1.95%)
EPCL 48.20 Increased By ▲ 0.05 (0.1%)
FCCL 23.96 Increased By ▲ 0.06 (0.25%)
FFBL 27.90 Decreased By ▼ -0.09 (-0.32%)
FFL 17.79 Decreased By ▼ -0.15 (-0.84%)
HASCOL 11.45 Increased By ▲ 0.25 (2.23%)
HUBC 78.30 Decreased By ▼ -0.70 (-0.89%)
HUMNL 8.64 Decreased By ▼ -0.08 (-0.92%)
JSCL 24.65 Increased By ▲ 0.35 (1.44%)
KAPCO 44.75 Increased By ▲ 0.06 (0.13%)
KEL 4.19 Decreased By ▼ -0.03 (-0.71%)
LOTCHEM 16.31 Decreased By ▼ -0.29 (-1.75%)
MLCF 46.70 Decreased By ▼ -0.35 (-0.74%)
PAEL 36.20 Increased By ▲ 0.32 (0.89%)
PIBTL 11.04 Decreased By ▼ -0.11 (-0.99%)
POWER 10.08 Decreased By ▼ -0.02 (-0.2%)
PPL 90.20 Decreased By ▼ -0.50 (-0.55%)
PRL 26.25 Increased By ▲ 0.31 (1.2%)
PTC 14.00 Increased By ▲ 0.99 (7.61%)
SILK 1.58 Increased By ▲ 0.02 (1.28%)
SNGP 48.20 Increased By ▲ 0.25 (0.52%)
TRG 168.50 Decreased By ▼ -3.30 (-1.92%)
UNITY 49.39 Increased By ▲ 0.14 (0.28%)
WTL 4.26 Increased By ▲ 0.01 (0.24%)
BR100 5,282 Increased By ▲ 24.37 (0.46%)
BR30 27,601 Increased By ▲ 45.56 (0.17%)
KSE100 48,305 Increased By ▲ 53.23 (0.11%)
KSE30 19,479 Decreased By ▼ -58.87 (-0.3%)
World

Swiss delay AstraZeneca COVID vaccine approval, order more shots from others

  • The country separately announced it had ordered millions more COVID-19 vaccine doses from other manufacturers.
  • As soon as the results have been received, a temporary authorisation according to the rolling procedure could be issued at very short notice.
03 Feb 2021

ZURICH: Switzerland has withheld approval for AstraZeneca's COVID-19 vaccine, drugs regulator Swissmedic said on Wednesday, demanding more efficacy and quality data before greenlighting a shot that won European Union approval last week.

The country separately announced it had ordered millions more COVID-19 vaccine doses from other manufacturers.

Switzerland, which has already ordered 5.3 million doses from AstraZeneca, said it was waiting on results from trials of the shot in North and South America involving tens of thousands of people, after earlier trials did not produce clear data including on efficacy in older people.

"As soon as the results have been received, a temporary authorisation according to the rolling procedure could be issued at very short notice," Swissmedic said in a statement, adding it was necessary to get additional data about safety, efficacy and quality.

"The data currently available do not point to a positive decision regarding benefits and risks," it said.

AstraZeneca did not immediately respond to a request for comment.

The company and its partner, Oxford University, have defended their vaccine, saying it had 76% efficacy against symptomatic infection for three months after a single dose, which increased if the second shot is delayed.

However, some European countries are restricting it to certain age groups, citing a lack of data in particular in older people.

The Swiss government said it had signed a deal with Germany's Curevac and the Swedish government for the delivery of 5 million vaccine doses, a preliminary pact with US vaccine maker Novavax for 6 million doses, and secured a further 6 million doses from Moderna.

These new orders bring total Swiss vaccine orders to more than 30 million doses, enough to vaccinate its 8.6 million population about twice over under a two-dose regimen.

Further talks with additional developers are under way for even more shots, the government said.

"The idea behind procuring vaccines from different manufacturers is to make sure that sufficient doses of an approved vaccine are available to the public even if there are delivery problems," the Federal Health Ministry said.